A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.